Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

us recorded revenue during the first quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the first quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $2.5 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its guidance for 2008 cash burn of $40 million to $60 million. The Company also stated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in tables 2 and 3, and are primarily due to:

-- Pre-tax stock compensation expense

-- Pre-tax charges for preferred stock accretion

-- Pre-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... 2014 Biotech companies make announcements ... drug systems and advanced Laboratory Instrumentation. Companies in focus ... BDX ), Thermo Fisher Scientific Inc. (NYSE: ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... the official language of the United States. Thats a bold move. ... ,For the first time, World Cup referees and their assistants ... order to be among the 44 officials taking part in soccers ... as its called in most of the world. But when it ...
... new phase. Both are headed to a jumpsuit jamboree courtesy of ... ex-heads of Enron - Ken Lay and Jeff Skilling - were ... of their fellow Houstonians. The duo will soon be sentenced before ... , , When Creative Becomes Criminal , ,It is ...
... company of a Florida manufacturer of radio frequency enabled ... following the signing of a bill prohibiting Wisconsin employers ... , ,Scott Silverman, chairman and CEO of Applied Digital, ... are consistent with what the law provides. "In theory, ...
Cached Biology Technology:English as the lingua franca of a new age: Its more powerful than any law 2English as the lingua franca of a new age: Its more powerful than any law 3Are there more Enrons out there? 2Are there more Enrons out there? 3Are there more Enrons out there? 4Company defends RFID implant product 2
(Date:9/18/2014)... PULLMAN, Wash. - Washington State University researchers have developed ... sediment to power waste cleanup in rural areas. ... lead to an inexpensive and quick way to clean ... treatment plants while reducing pollution. , Professor Haluk ... College of Engineering and Architecture discuss the system in ...
(Date:9/18/2014)... sleep-promoting circuit located deep in the primitive brainstem has ... researchers at Harvard School of Medicine and the University ... is only the second "sleep node" identified in the ... and sufficient to produce deep sleep. , Published online ... demonstrates that fully half of all of the brain,s ...
(Date:9/18/2014)... SAN ANTONIO, September 18, 2014 New research into ... which causes a severe hemorrhagic disease in humans similar ... factors essential for CCHFV infection. This discovery has the ... against the pathogen. , The research, reported ... PLoS Pathogens and conducted by scientists at the ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2
... the Feb. 8 PNAS supports the concept of a ... California, Israel, and Germany have compared three distantly related ... ?and reported that protein "wiring" connections in one species ... of three higher level organisms published in the February ...
... baculovirus and caterpillar cells scientists from Protein Sciences Corporation ... in the development of an experimental cell-based influenza vaccine. ... Society for Microbiology Biodefense Research Meeting. , "The bird ... could happen at any time," says Keyang Wang, a ...
... Agilent Technologies Inc. (NYSE: A) today released an ... of biological systems. The tool is available as ... bioinformatics platform that enables researchers to form a ... understanding of molecular pathways and the biological causes ...
Cached Biology News:Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 2Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 3Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 4Influenza vaccine uses insect cells to speed development 2Agilent Technologies releases automated literature search tool for biology researchers 2Agilent Technologies releases automated literature search tool for biology researchers 3
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: